-
1
-
-
75849140253
-
National health statistics reports
-
summary. Available from, Accessed November 19, 2008
-
Centers for Disease Control and Prevention. National health statistics reports. National ambulatory Medicare care survey: 2006 summary. Available from http://www.cdc.gov/nchs/ data/nhsr/nhsr003.pdf. Accessed November 19, 2008.
-
(2006)
National ambulatory Medicare care survey
-
-
-
2
-
-
33744490162
-
Drug therapy for hypercholesterolemia and dyslipidemia
-
Brunton LL, Lazo JS, Parker KL, et al, eds, 11th ed. Columbus, OH: McGraw-Hill Companies, Inc
-
Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL, Lazo JS, Parker KL, et al, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. Columbus, OH: McGraw-Hill Companies, Inc., 2006:933.
-
(2006)
Goodman & Gilman's the pharmacological basis of therapeutics
, pp. 933
-
-
Mahley, R.W.1
Bersot, T.P.2
-
3
-
-
75849149174
-
-
Agency for Healthcare Research and Quality. Statistical brief #205. Trends in statins utilization and expenditures for the U.S. civilian noninstitutionalized population, 2000 and 2005. Available from http://www.meps.ahrq.gov/mepsweb/data-files/publications/st205/stat205.pdf. Accessed November 26, 2008.
-
Agency for Healthcare Research and Quality. Statistical brief #205. Trends in statins utilization and expenditures for the U.S. civilian noninstitutionalized population, 2000 and 2005. Available from http://www.meps.ahrq.gov/mepsweb/data-files/publications/st205/stat205.pdf. Accessed November 26, 2008.
-
-
-
-
4
-
-
14844292583
-
Cancer risk among statin users: A population-based cohort study
-
Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005;114:643-7.
-
(2005)
Int J Cancer
, vol.114
, pp. 643-647
-
-
Friis, S.1
Poulsen, A.H.2
Johnsen, S.P.3
-
5
-
-
24344484721
-
The role of statins in cancer prevention and treatment
-
Stamm JA, Ornstein DL. The role of statins in cancer prevention and treatment. Oncology (Williston Park) 2005;19:739-54.
-
(2005)
Oncology (Williston Park)
, vol.19
, pp. 739-754
-
-
Stamm, J.A.1
Ornstein, D.L.2
-
6
-
-
0001504829
-
Simvastatin strongly reduces the levels of Alzheimer's disease β-amyloid peptide Aβ42 and Aβ40 in vitro and in vivo
-
Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces the levels of Alzheimer's disease β-amyloid peptide Aβ42 and Aβ40 in vitro and in vivo. Proc Acad Sci USA 2001;98:5856-61.
-
(2001)
Proc Acad Sci USA
, vol.98
, pp. 5856-5861
-
-
Fassbender, K.1
Simons, M.2
Bergmann, C.3
-
7
-
-
0034709764
-
Oral statins and increased bone-mineral density in postmenopausal women
-
Edwards CJ, Hart DJ, Spectore TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000;355:2218-19.
-
(2000)
Lancet
, vol.355
, pp. 2218-2219
-
-
Edwards, C.J.1
Hart, D.J.2
Spectore, T.D.3
-
8
-
-
0035138445
-
Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia
-
Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001;77:247-53.
-
(2001)
Int J Cardiol
, vol.77
, pp. 247-253
-
-
Musial, J.1
Undas, A.2
Gajewski, P.3
Jankowski, M.4
Sydor, W.5
Szczeklik, A.6
-
9
-
-
0033454062
-
Effect of the HMGCoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia
-
Glorioso N, Manunta P, Filigheddu F, et al. Effect of the HMGCoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-6.
-
(1999)
Hypertension
, vol.34
, pp. 1281-1286
-
-
Glorioso, N.1
Manunta, P.2
Filigheddu, F.3
-
10
-
-
1242295184
-
Statin therapy is associated with improved survival in ischemic and nonischemic heart failure
-
Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and nonischemic heart failure. J Am Coll Cardiol 2004;43:642-8.
-
(2004)
J Am Coll Cardiol
, vol.43
, pp. 642-648
-
-
Horwich, T.B.1
MacLellan, W.R.2
Fonarow, G.C.3
-
11
-
-
0036694809
-
Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure
-
Horwich TB, Hamilton MA, MacLellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002;8:216-24.
-
(2002)
J Card Fail
, vol.8
, pp. 216-224
-
-
Horwich, T.B.1
Hamilton, M.A.2
MacLellan, W.R.3
Fonarow, G.C.4
-
12
-
-
41449093519
-
Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials
-
Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336:645-51.
-
(2008)
BMJ
, vol.336
, pp. 645-651
-
-
Strippoli, G.F.1
Navaneethan, S.D.2
Johnson, D.W.3
-
13
-
-
39149086751
-
Cholesterol modulates cellular TGF-β responsiveness by altering TGF-β binding to TGF-β receptors
-
Chen CL, Huang SS, Huang JS. Cholesterol modulates cellular TGF-β responsiveness by altering TGF-β binding to TGF-β receptors. J Cell Physiol 2008;215:223-33.
-
(2008)
J Cell Physiol
, vol.215
, pp. 223-233
-
-
Chen, C.L.1
Huang, S.S.2
Huang, J.S.3
-
14
-
-
0034948339
-
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site
-
Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-92.
-
(2001)
Nat Med
, vol.7
, pp. 687-692
-
-
Weitz-Schmidt, G.1
Welzenbach, K.2
Brinkmann, V.3
-
15
-
-
0038724543
-
Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation
-
Houten SM, Frenkel J, Waterham HR. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell Mol Life Sci 2003;60:1118-34.
-
(2003)
Cell Mol Life Sci
, vol.60
, pp. 1118-1134
-
-
Houten, S.M.1
Frenkel, J.2
Waterham, H.R.3
-
16
-
-
0026718746
-
Serum cholesterol and cancer risk: An epidemiologic perspective
-
Kritchevsky SB, Kritchevsky D. Serum cholesterol and cancer risk: an epidemiologic perspective. Annu Rev Nutr 1992;12:391-416.
-
(1992)
Annu Rev Nutr
, vol.12
, pp. 391-416
-
-
Kritchevsky, S.B.1
Kritchevsky, D.2
-
17
-
-
0025723999
-
Studies on the mechanism of simvastatin-induced thyroid hypertrophy and follicular cell adenoma in the rat
-
Smith PF, Grossman SJ, Gerson RJ, et al. Studies on the mechanism of simvastatin-induced thyroid hypertrophy and follicular cell adenoma in the rat. Toxicol Pathol 1991;19:197-205.
-
(1991)
Toxicol Pathol
, vol.19
, pp. 197-205
-
-
Smith, P.F.1
Grossman, S.J.2
Gerson, R.J.3
-
18
-
-
0032728548
-
Lovastatin induces mitotic abnormalities in various cell lines
-
Lamprecht J, Wojcik C, Jakobisiak M, Stoehr M, Schrorter D, Paweletz N. Lovastatin induces mitotic abnormalities in various cell lines. Cell Biol Int 1999;23:51-60.
-
(1999)
Cell Biol Int
, vol.23
, pp. 51-60
-
-
Lamprecht, J.1
Wojcik, C.2
Jakobisiak, M.3
Stoehr, M.4
Schrorter, D.5
Paweletz, N.6
-
19
-
-
0031081522
-
Synthesis and biological activity of methane sulfonyl pyrrolesubstituted 3,4-dihydroxy-6-heptanoates: A novel series of HMG-CoA reductase inhibitors
-
Watanabe M, Koike H, Ishiba T, Okada T, Seo S, Hirai K. Synthesis and biological activity of methane sulfonyl pyrrolesubstituted 3,4-dihydroxy-6-heptanoates: a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem 1997;5:437-44.
-
(1997)
Bioorg Med Chem
, vol.5
, pp. 437-444
-
-
Watanabe, M.1
Koike, H.2
Ishiba, T.3
Okada, T.4
Seo, S.5
Hirai, K.6
-
21
-
-
0032534660
-
Dolichol-like lipids with stimulatory effect on DNA synthesis: Substrates for protein dolichylation?
-
Wejde J, Hjertman M, Carlberg M, et al. Dolichol-like lipids with stimulatory effect on DNA synthesis: substrates for protein dolichylation? J Cell Biochem 1998;71:502-14.
-
(1998)
J Cell Biochem
, vol.71
, pp. 502-514
-
-
Wejde, J.1
Hjertman, M.2
Carlberg, M.3
-
22
-
-
0035908493
-
Blocking oncogenic Ras signaling for cancer therapy
-
Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-74.
-
(2001)
J Natl Cancer Inst
, vol.93
, pp. 1062-1074
-
-
Adjei, A.A.1
-
23
-
-
0242290258
-
p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases
-
Okumadu C, Dutta A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol Chem 2003;278:43586-94.
-
(2003)
J Biol Chem
, vol.278
, pp. 43586-43594
-
-
Okumadu, C.1
Dutta, A.2
-
24
-
-
29044440878
-
Anti-angiogenic and anti-inflammatory effects of statins: Relevance to anti-cancer therapy
-
Dulak J, Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets 2005;5:579-94.
-
(2005)
Curr Cancer Drug Targets
, vol.5
, pp. 579-594
-
-
Dulak, J.1
Jozkowicz, A.2
-
25
-
-
10744220087
-
Statins differentially regulate vascular endothelial growth factor in endothelial and vascular smooth muscle cells
-
Frick M, Dulak J, Cisowski J, et al. Statins differentially regulate vascular endothelial growth factor in endothelial and vascular smooth muscle cells. Atherosclerosis 2003;170:229-36.
-
(2003)
Atherosclerosis
, vol.170
, pp. 229-236
-
-
Frick, M.1
Dulak, J.2
Cisowski, J.3
-
26
-
-
75849119575
-
Does statin treatment alter VEGF and HIF expression in human colorectal cancer? An immunohistochemical (IHC) approach: Lower gastrointestinal 10328 [abstract]
-
De Four KJS, Paleolog E, Sandison A, Cohen P, Dawson PM. Does statin treatment alter VEGF and HIF expression in human colorectal cancer? An immunohistochemical (IHC) approach: lower gastrointestinal 10328 [abstract]. Br J Surg 2006;93:229.
-
(2006)
Br J Surg
, vol.93
, pp. 229
-
-
De Four, K.J.S.1
Paleolog, E.2
Sandison, A.3
Cohen, P.4
Dawson, P.M.5
-
27
-
-
0033826581
-
The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals
-
Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-10.
-
(2000)
Nat Med
, vol.6
, pp. 1004-1010
-
-
Kureishi, Y.1
Luo, Z.2
Shiojima, I.3
-
28
-
-
0035834823
-
Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins
-
Brouet A, Sonveaux P, Dessy C, et al. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 2001;89:866-73.
-
(2001)
Circ Res
, vol.89
, pp. 866-873
-
-
Brouet, A.1
Sonveaux, P.2
Dessy, C.3
-
30
-
-
2942545972
-
Statins prevent oxidized low-density lipoprotein- and lysophosphatidylcholineinduced proliferation of human endothelial cells
-
Schaefer CA, Kuhlmann CR, Gast C, et al. Statins prevent oxidized low-density lipoprotein- and lysophosphatidylcholineinduced proliferation of human endothelial cells. Vasc Pharmacol 2004;41:67-73.
-
(2004)
Vasc Pharmacol
, vol.41
, pp. 67-73
-
-
Schaefer, C.A.1
Kuhlmann, C.R.2
Gast, C.3
-
31
-
-
0033758875
-
Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation
-
Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology 2000;59:245-54.
-
(2000)
Oncology
, vol.59
, pp. 245-254
-
-
Wang, I.K.1
Lin-Shiau, S.Y.2
Lin, J.K.3
-
32
-
-
0035874879
-
Inhibition of epidermal growth factor - induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors
-
Kusama T, Mukai M, Iwasaki T, et al. Inhibition of epidermal growth factor - induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors. Cancer Res 2001;61:4885-91.
-
(2001)
Cancer Res
, vol.61
, pp. 4885-4891
-
-
Kusama, T.1
Mukai, M.2
Iwasaki, T.3
-
33
-
-
0034614637
-
The hallmarks of cancer
-
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
-
(2000)
Cell
, vol.100
, pp. 57-70
-
-
Hanahan, D.1
Weinberg, R.A.2
-
34
-
-
3042736080
-
Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention
-
Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med 2004;229:567-85.
-
(2004)
Exp Biol Med
, vol.229
, pp. 567-585
-
-
Mo, H.1
Elson, C.E.2
-
35
-
-
19844367157
-
Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells
-
Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005;26:883-91.
-
(2005)
Carcinogenesis
, vol.26
, pp. 883-891
-
-
Cafforio, P.1
Dammacco, F.2
Gernone, A.3
Silvestris, F.4
-
36
-
-
0033536298
-
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
-
Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70-6.
-
(1999)
N Engl J Med
, vol.341
, pp. 70-76
-
-
Pitt, B.1
Waters, D.2
Brown, W.V.3
-
37
-
-
0034633814
-
Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The simvastatin/enalapril coronary atherosclerosis trial (SCAT)
-
Teo KK, Burton JR, Buller CR, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the simvastatin/enalapril coronary atherosclerosis trial (SCAT). Circulation 2000;102:1748-54.
-
(2000)
Circulation
, vol.102
, pp. 1748-1754
-
-
Teo, K.K.1
Burton, J.R.2
Buller, C.R.3
-
38
-
-
0037132607
-
ALLHAT Officers and Coordinators. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care
-
ALLHAT Officers and Coordinators. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 2002;288:2998-3007.
-
(2002)
JAMA
, vol.288
, pp. 2998-3007
-
-
-
39
-
-
15944410609
-
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
-
LaRosa JC, Grudy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
-
(2005)
N Engl J Med
, vol.352
, pp. 1425-1435
-
-
LaRosa, J.C.1
Grudy, S.M.2
Waters, D.D.3
-
40
-
-
27744603499
-
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study - a randomized controlled trial
-
Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study - a randomized controlled trial. JAMA 2005;294:2437-45.
-
(2005)
JAMA
, vol.294
, pp. 2437-2445
-
-
Pedersen, T.R.1
Faergeman, O.2
Kastelein, J.J.P.3
-
41
-
-
36448964544
-
Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack
-
Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack. Stroke 2007:38:3198-204.
-
(2007)
Stroke
, vol.38
, pp. 3198-3204
-
-
Amarenco, P.1
Goldstein, L.B.2
Szarek, M.3
-
42
-
-
0032572086
-
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
-
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
-
(1998)
JAMA
, vol.279
, pp. 1615-1622
-
-
Downs, J.R.1
Clearfield, M.2
Weis, S.3
-
43
-
-
0027488722
-
Coronary angiographic changes with lovastatin therapy: The monitored atherosclerosis regression study (MARS)
-
Blankenhorn DH, Azen ST, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the monitored atherosclerosis regression study (MARS). Ann Intern Med 1993;119:969-76.
-
(1993)
Ann Intern Med
, vol.119
, pp. 969-976
-
-
Blankenhorn, D.H.1
Azen, S.T.2
Kramsch, D.M.3
-
44
-
-
0028883828
-
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
-
Shepard J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
-
(1995)
N Engl J Med
, vol.333
, pp. 1301-1307
-
-
Shepard, J.1
Cobbe, S.M.2
Ford, I.3
-
45
-
-
0032487931
-
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
-
LIPID Study Group
-
LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
-
(1998)
N Engl J Med
, vol.339
, pp. 1349-1357
-
-
-
46
-
-
10744229858
-
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomized, placebo-controlled trial
-
Hallvard H, Fellstrom B, Jardine AG. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomized, placebo-controlled trial. Lancet 2003;361:2024-31.
-
(2003)
Lancet
, vol.361
, pp. 2024-2031
-
-
Hallvard, H.1
Fellstrom, B.2
Jardine, A.G.3
-
47
-
-
0037178569
-
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial
-
Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22.
-
(2002)
JAMA
, vol.287
, pp. 3215-3222
-
-
Serruys, P.W.1
de Feyter, P.2
Macaya, C.3
-
48
-
-
22344458137
-
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
-
Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48.
-
(2005)
N Engl J Med
, vol.353
, pp. 238-248
-
-
Wanner, C.1
Krane, V.2
Marz, W.3
-
49
-
-
0027987849
-
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
-
Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
-
(1994)
Lancet
, vol.344
, pp. 1383-1389
-
-
Pedersen, T.R.1
Kjekshus, J.2
Berg, K.3
-
50
-
-
4444252160
-
Mortality and incidence of cancer during 10-year follow-up of the Scandinavian simvastatin survival study (4S)
-
Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian simvastatin survival study (4S). Lancet 2004;364:771-7.
-
(2004)
Lancet
, vol.364
, pp. 771-777
-
-
Strandberg, T.E.1
Pyorala, K.2
Cook, T.J.3
-
51
-
-
0037164314
-
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial
-
Sheperd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-30.
-
(2002)
Lancet
, vol.360
, pp. 1623-1630
-
-
Sheperd, J.1
Blauw, G.J.2
Murphy, M.B.3
-
52
-
-
0342981862
-
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
-
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
-
(1996)
N Engl J Med
, vol.335
, pp. 1001-1009
-
-
Sacks, F.M.1
Pfeffer, M.A.2
Moye, L.A.3
-
53
-
-
35248901000
-
Long-term follow-up of the west of Scotland coronary prevention study
-
Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the west of Scotland coronary prevention study. N Engl J Med 2007;357:1477-86.
-
(2007)
N Engl J Med
, vol.357
, pp. 1477-1486
-
-
Ford, I.1
Murray, H.2
Packard, C.J.3
Shepherd, J.4
Macfarlane, P.W.5
Cobbe, S.M.6
-
56
-
-
38649095993
-
Screening statins for possible carcinogenic risk: Up to 9 years of follow-up of 361,859 recipients
-
Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36.
-
(2008)
Pharmacoepidemiol Drug Saf
, vol.17
, pp. 27-36
-
-
Friedman, G.D.1
Flick, E.D.2
Udaltsova, N.3
Chan, J.4
Quesenberry, C.P.5
Habel, L.A.6
-
57
-
-
0034726387
-
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer
-
Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer. Arch Intern Med 2000;160:2363-8.
-
(2000)
Arch Intern Med
, vol.160
, pp. 2363-2368
-
-
Blais, L.1
Desgagne, A.2
LeLorier, J.3
-
58
-
-
1542329169
-
Statin use and cancer risk in the general practice research database
-
Kaye JA, Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer 2004;90:635-7.
-
(2004)
Br J Cancer
, vol.90
, pp. 635-637
-
-
Kaye, J.A.1
Jick, H.2
-
59
-
-
2942754163
-
The risk of cancer in users of statins
-
Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004;22:2388-94.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2388-2394
-
-
Graaf, M.R.1
Beiderbeck, A.B.2
Egberts, A.C.G.3
Richel, D.J.4
Guchelaar, H.J.5
-
60
-
-
38449120272
-
The association between statins and cancer incidence in a veteran population
-
Farwell WR, Scranton RE, Lawler EV, et al. The association between statins and cancer incidence in a veteran population. J Natl Cancer Inst 2008;100:134-9.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 134-139
-
-
Farwell, W.R.1
Scranton, R.E.2
Lawler, E.V.3
-
61
-
-
34248580619
-
Statins reduce the risk of lung cancer in humans: A large case-control study of U.S. veterans
-
Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of U.S. veterans. Chest 2007;131:1282-8.
-
(2007)
Chest
, vol.131
, pp. 1282-1288
-
-
Khurana, V.1
Bejjanki, H.R.2
Caldito, G.3
Owens, M.W.4
-
62
-
-
18744387733
-
The effect of statins of serum prostate specific antigen levels in a cohort of airline pilots: A preliminary report
-
Cyrus-David MS, Weinberg A, Whompson T, Kadmon D. The effect of statins of serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 2005;173:1923-5.
-
(2005)
J Urol
, vol.173
, pp. 1923-1925
-
-
Cyrus-David, M.S.1
Weinberg, A.2
Whompson, T.3
Kadmon, D.4
-
63
-
-
23944487796
-
Statins and prostate cancer risk: A case-control study
-
Shannon J, Tewoderos S, Garzotto M, et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005;162:318-25.
-
(2005)
Am J Epidemiol
, vol.162
, pp. 318-325
-
-
Shannon, J.1
Tewoderos, S.2
Garzotto, M.3
-
65
-
-
33646949251
-
Statin use and breast cancer: Prospective results from the women's health initiative
-
Cauley JA, McTiernan A, Rodabough RJ, et al. Statin use and breast cancer: prospective results from the women's health initiative. J Natl Cancer Inst 2006;98:700-7.
-
(2006)
J Natl Cancer Inst
, vol.98
, pp. 700-707
-
-
Cauley, J.A.1
McTiernan, A.2
Rodabough, R.J.3
-
66
-
-
27644560871
-
Serum lipids, lipid-lowering drugs, and the risk of breast cancer
-
Eliassen AH, Colditz GA, Rosner B, Willet WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 2005;165:2264-71.
-
(2005)
Arch Intern Med
, vol.165
, pp. 2264-2271
-
-
Eliassen, A.H.1
Colditz, G.A.2
Rosner, B.3
Willet, W.C.4
Hankinson, S.E.5
-
69
-
-
66949119287
-
Statins and the risk of colorectal carcinoma: A nested casecontrol study in veterans with diabetes
-
Hachem C, Morgan R, Johnson M, Keubeler M, El-Serag H. Statins and the risk of colorectal carcinoma: a nested casecontrol study in veterans with diabetes. Am J Gastroenterol 2009;104:1241-8.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 1241-1248
-
-
Hachem, C.1
Morgan, R.2
Johnson, M.3
Keubeler, M.4
El-Serag, H.5
-
70
-
-
65249190240
-
Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes
-
El-Serag HA, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009;136:1601-8.
-
(2009)
Gastroenterology
, vol.136
, pp. 1601-1608
-
-
El-Serag, H.A.1
Johnson, M.L.2
Hachem, C.3
Morgana, R.O.4
-
71
-
-
29944446607
-
Statins and cancer risk: A meta-analysis
-
Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80.
-
(2006)
JAMA
, vol.295
, pp. 74-80
-
-
Dale, K.M.1
Coleman, C.I.2
Henyan, N.N.3
Kluger, J.4
White, C.M.5
|